L Corash

Summary

Publications

  1. ncbi request reprint Evaluation of bacterial inactivation in prestorage pooled, leukoreduced, whole blood-derived platelet concentrates suspended in plasma prepared with photochemical treatment
    Mark E Brecher
    Department of Pathology and Laboratory Medicine, University of North Carolina, 101 Manning Drive, Chapel Hill, NC 27514, USA
    Transfusion 47:1896-901. 2007
  2. ncbi request reprint Inactivation of viruses, bacteria, protozoa, and leukocytes in platelet concentrates
    L Corash
    Cerus Corporation, San Francisco, USA
    Vox Sang 74:173-6. 1998
  3. ncbi request reprint Inactivation of viruses, bacteria, protozoa and leukocytes in platelet and red cell concentrates
    L Corash
    Cerus Corporation, San Francisco, Concord, CA 94520, USA
    Vox Sang 78:205-10. 2000
  4. ncbi request reprint Inactivation of infectious pathogens in labile blood components: meeting the challenge
    L Corash
    Cerus Corporation and Department of Laboratory Medicine, University of California, San Francisco, Concord, CA 94520, United States
    Transfus Clin Biol 8:138-45. 2001
  5. ncbi request reprint Pathogen reduction technology: methods, status of clinical trials, and future prospects
    Laurence Corash
    Cerus Corporation and Department of Laboratory Medicine, University of California San Francisco, 2411 Stanwell Drive, Concord, CA 94520, USA
    Curr Hematol Rep 2:495-502. 2003
  6. ncbi request reprint Confounding variables and co-interventions in the design of clinical trials: real life experience
    Laurence Corash
    Cerus Corporation, Concord, CA, USA
    Vox Sang 83:261-6. 2002
  7. ncbi request reprint Inactivation of leukocytes in platelet concentrates by photochemical treatment with psoralen plus UVA
    J A Grass
    Cerus Corp, Concord, CA 94520, USA
    Blood 91:2180-8. 1998
  8. ncbi request reprint Elimination of cytokine production in stored platelet concentrate aliquots by photochemical treatment with psoralen plus ultraviolet A light
    D J Hei
    Cerus Corp, Concord, California 94520, USA
    Transfusion 39:239-48. 1999
  9. ncbi request reprint Fresh frozen plasma prepared with amotosalen HCl (S-59) photochemical pathogen inactivation: transfusion of patients with congenital coagulation factor deficiencies
    Pedro de Alarcon
    Department of Pediatric Hematology, University of Virginia, Charlottesville, Virginia, USA
    Transfusion 45:1362-72. 2005
  10. ncbi request reprint Photochemical treatment of plasma with amotosalen and long-wavelength ultraviolet light inactivates pathogens while retaining coagulation function
    Yasmin Singh
    Cerus Corp, Concord, California 94520, USA
    Transfusion 46:1168-77. 2006

Collaborators

  • Jeffrey McCullough
  • Richard J Benjamin
  • P D Mintz
  • Sherrill Slichter
  • Jean Claude Osselaer
  • Yasmin Singh
  • L T Goodnough
  • Miguel Lozano Molero
  • Ritchard G Cable
  • J P Allain
  • Olivier Garraud
  • Tor Hervig
  • M E Brecher
  • Per Ljungman
  • Hans Gulliksson
  • Lily Lin
  • Edward Snyder
  • Peyton Metzel
  • Julie Hambleton
  • Maureen G Conlan
  • David Wages
  • Fabrice Cognasse
  • Peter Schlenke
  • Miguel Lozano
  • Linda Pinkoski
  • Scott Murphy
  • Jorge A Rios
  • Ronald G Strauss
  • Jean Pierre Cazenave
  • Jin Sying Lin
  • Iris Bruchmüller
  • Pedro de Alarcon
  • Helen Yarranton
  • Veronique Mayaudon
  • Ulf Staginnus
  • Martin Lee
  • Kathryn Davis
  • D J Hei
  • Dick van Rhenen
  • Jean Marc Payrat
  • Patricia Chavarin
  • Marie Louise Wiesel
  • Herve Isola
  • Daniel Kientz
  • Gines Escolar
  • Ana Galan
  • L Lin
  • Roberto Mazzara
  • Tibor Greenwalt
  • Gail Sindermann
  • J A Grass
  • Maurene Viele
  • David Cook
  • Neeta Rugg
  • Thomas Abshire
  • Craig Kessler
  • Peter Smith
  • Karin Janetzko
  • Marion Dugdale
  • Rinah Shopnick
  • Ian J Mackie
  • Harold Klüter
  • Kristen A Bernard
  • Idith Ortiz
  • Alice Cohen
  • Samuel J Machin
  • Ileana Lopez-Plaza
  • Valerie Jauvin
  • Prasad Matthew
  • Peter Bugert
  • Barbara A Konkle
  • Michael Streiff
  • Andrew S Lawrie
  • Harvey J Alter
  • Carl V Hanson
  • Krishna K Murthy
  • Robert Lane
  • Thomas Raife
  • Barbara Molini
  • D H Buchholz
  • George Cimino
  • Sheila A Lukehart
  • Laurene Baril
  • Roberta Dikeman
  • Kent Dupuis
  • Margaret Rheinschmidt
  • Derwood Pamphilon
  • Harald Kluter
  • Maureen Conlan
  • Stephane Marblie

Detail Information

Publications32

  1. ncbi request reprint Evaluation of bacterial inactivation in prestorage pooled, leukoreduced, whole blood-derived platelet concentrates suspended in plasma prepared with photochemical treatment
    Mark E Brecher
    Department of Pathology and Laboratory Medicine, University of North Carolina, 101 Manning Drive, Chapel Hill, NC 27514, USA
    Transfusion 47:1896-901. 2007
    ..Because PLT additive solutions (ASs) are not used in the United States, this study evaluated the ability of the PCT process to inactivate low levels of bacteria in pooled whole blood-derived PLTs (RDP) suspended in 100 percent plasma...
  2. ncbi request reprint Inactivation of viruses, bacteria, protozoa, and leukocytes in platelet concentrates
    L Corash
    Cerus Corporation, San Francisco, USA
    Vox Sang 74:173-6. 1998
    ..During the past decade a number of methods to inactivate infectious pathogens in blood components, including platelets, have been developed. This technology is now entering the clinical trial phase...
  3. ncbi request reprint Inactivation of viruses, bacteria, protozoa and leukocytes in platelet and red cell concentrates
    L Corash
    Cerus Corporation, San Francisco, Concord, CA 94520, USA
    Vox Sang 78:205-10. 2000
    ..The paradigm for this possibility is the HIV pandemic, which erupted in 1979. During the past decade a number of methods to inactivate infectious pathogens have been developed and have entered the advanced clinical trial phase...
  4. ncbi request reprint Inactivation of infectious pathogens in labile blood components: meeting the challenge
    L Corash
    Cerus Corporation and Department of Laboratory Medicine, University of California, San Francisco, Concord, CA 94520, United States
    Transfus Clin Biol 8:138-45. 2001
    ..During the past decade a number of methods to inactivate infectious pathogens in labile blood components have been developed and have entered the advanced clinical trial phase...
  5. ncbi request reprint Pathogen reduction technology: methods, status of clinical trials, and future prospects
    Laurence Corash
    Cerus Corporation and Department of Laboratory Medicine, University of California San Francisco, 2411 Stanwell Drive, Concord, CA 94520, USA
    Curr Hematol Rep 2:495-502. 2003
    ..These technologies offer the potential for a paradigm shift to further improve the safety of blood transfusion...
  6. ncbi request reprint Confounding variables and co-interventions in the design of clinical trials: real life experience
    Laurence Corash
    Cerus Corporation, Concord, CA, USA
    Vox Sang 83:261-6. 2002
  7. ncbi request reprint Inactivation of leukocytes in platelet concentrates by photochemical treatment with psoralen plus UVA
    J A Grass
    Cerus Corp, Concord, CA 94520, USA
    Blood 91:2180-8. 1998
    ..Therefore, PCT has the potential to reduce the incidence of leukocyte-mediated adverse immune reactions associated with platelet transfusion...
  8. ncbi request reprint Elimination of cytokine production in stored platelet concentrate aliquots by photochemical treatment with psoralen plus ultraviolet A light
    D J Hei
    Cerus Corp, Concord, California 94520, USA
    Transfusion 39:239-48. 1999
    ....
  9. ncbi request reprint Fresh frozen plasma prepared with amotosalen HCl (S-59) photochemical pathogen inactivation: transfusion of patients with congenital coagulation factor deficiencies
    Pedro de Alarcon
    Department of Pediatric Hematology, University of Virginia, Charlottesville, Virginia, USA
    Transfusion 45:1362-72. 2005
    ..Photochemical treatment (PCT) with amotosalen HCl (S-59) was developed to inactivate pathogens and white blood cells in plasma (PCT-FFP) used for transfusion support...
  10. ncbi request reprint Photochemical treatment of plasma with amotosalen and long-wavelength ultraviolet light inactivates pathogens while retaining coagulation function
    Yasmin Singh
    Cerus Corp, Concord, California 94520, USA
    Transfusion 46:1168-77. 2006
    ..These studies evaluated the efficacy of PCT to inactivate pathogens in plasma and the effect of PCT on plasma function...
  11. ncbi request reprint Clinical safety of platelets photochemically treated with amotosalen HCl and ultraviolet A light for pathogen inactivation: the SPRINT trial
    Edward Snyder
    Yale University Medical School, Yale New Haven Hospital, New Haven, Connecticut, USA
    Transfusion 45:1864-75. 2005
    ..Hemostatic equivalency was demonstrated. The proportion of patients with Grade 2 bleeding was not inferior for PCT PLTs...
  12. ncbi request reprint Inactivation of viruses in platelet concentrates by photochemical treatment with amotosalen and long-wavelength ultraviolet light
    Lily Lin
    Cerus Corporation, Concord, California, USA
    Transfusion 45:580-90. 2005
    ..A photochemical treatment (PCT) process with amotosalen-HCl and long-wavelength ultraviolet light (UVA), which cross-links nucleic acids, was developed to inactivate viruses and other pathogens in PLT concentrates...
  13. ncbi request reprint Photochemical treatment of platelet concentrates with amotosalen and long-wavelength ultraviolet light inactivates a broad spectrum of pathogenic bacteria
    Lily Lin
    Cerus Corporation, Concord, California 94520, USA
    Transfusion 44:1496-504. 2004
    ..A photochemical treatment (PCT) process with amotosalen HCl and long-wavelength ultraviolet light (UVA), which cross-links nucleic acids, was developed to inactivate bacteria and other pathogens in PLT concentrates...
  14. ncbi request reprint Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial
    Jeffrey McCullough
    University of Minnesota, MMC 609, 420 Delaware Street SE, Minneapolis, MN 55455, USA
    Blood 104:1534-41. 2004
    ..02). The incidence of grade 2 bleeding was equivalent for PCT and conventional platelets, although posttransfusion platelet count increments and days to next transfusion were decreased for PCT compared with conventional platelets...
  15. ncbi request reprint Platelets photochemically treated with amotosalen HCl and ultraviolet A light correct prolonged bleeding times in patients with thrombocytopenia
    Sherrill J Slichter
    Puget Sound Blood Center, Seattle, Washington 98104 1256, USA
    Transfusion 46:731-40. 2006
    ..Photochemical treatment (PCT) with amotosalen HCl with ultraviolet A illumination inactivates pathogens and white blood cells in platelet (PLT) concentrates...
  16. ncbi request reprint Leukoreduced buffy coat-derived platelet concentrates photochemically treated with amotosalen HCl and ultraviolet A light stored up to 7 days: assessment of hemostatic function under flow conditions
    Miguel Lozano
    Department of Hemotherapy and Hemostasis, Hospital Clinic Provincial, University of Barcelona, Barcelona, Spain
    Transfusion 47:666-71. 2007
    ..Adhesion and aggregation of PLTs to injured vascular surfaces are critical aspects of PLT hemostatic function...
  17. ncbi request reprint Quantification of viral inactivation by photochemical treatment with amotosalen and UV A light, using a novel polymerase chain reaction inhibition method with preamplification
    Jean Pierre Allain
    University of Cambridge, Cambridge, United Kingdom
    J Infect Dis 194:1737-44. 2006
    ..We evaluated a novel, efficient polymerase chain reaction (PCR) inhibition assay and examined correlations with reductions in infectivity...
  18. ncbi request reprint Viability of red cells prepared with S-303 pathogen inactivation treatment
    Jorge A Rios
    American Red Cross Blood Services, Dedham, Massachusetts, USA
    Transfusion 46:1778-86. 2006
    ..A nucleic acid-targeted pathogen inactivation process with S-303 was developed to treat red blood cells (RBCs)...
  19. ncbi request reprint A randomized, controlled Phase III trial of therapeutic plasma exchange with fresh-frozen plasma (FFP) prepared with amotosalen and ultraviolet A light compared to untreated FFP in thrombotic thrombocytopenic purpura
    Paul D Mintz
    University of Virginia Health System, Charlottesville, Virginia, USA
    Transfusion 46:1693-704. 2006
    ....
  20. doi request reprint Photochemical treatment of plasma with amotosalen and UVA light: process validation in three European blood centers
    Peter Schlenke
    University of Lubeck, Institute of Immunology and Transfusion Medicine, Lubeck, Germany
    Transfusion 48:697-705. 2008
    ..Process validation studies were performed in three European blood centers under routine operating conditions...
  21. doi request reprint Release of immune modulation factors from platelet concentrates during storage after photochemical pathogen inactivation treatment
    Fabrice Cognasse
    Blood Transfusion Center, EFS Auvergne Loire, Saint Etienne, France
    Transfusion 48:809-13. 2008
    ..This study examined the effects of photochemical pathogen inactivation treatment (PCT) on the release of cytokines and/or chemokines from PLT components...
  22. ncbi request reprint Photochemically treated fresh frozen plasma for transfusion of patients with acquired coagulopathy of liver disease
    Paul D Mintz
    Department of Pathology, University of Virginia, Charlottesville, 22908 0286, USA
    Blood 107:3753-60. 2006
    ..No differences were observed in use of blood components, clinical hemostasis, or safety. These results suggest PCT-FFP supported hemostasis in the treatment of acquired coagulopathy similarly to conventional FFP...
  23. ncbi request reprint Platelet dose consistency and its effect on the number of platelet transfusions for support of thrombocytopenia: an analysis of the SPRINT trial of platelets photochemically treated with amotosalen HCl and ultraviolet A light
    Scott Murphy
    American Red Cross Blood Services, Philadelphia, Pennsylvania, USA
    Transfusion 46:24-33. 2006
    ..PLT dose was analyzed to determine the impact of the number of PLTs transfused on transfusion requirements...
  24. ncbi request reprint Pharmacokinetic study of FFP photochemically treated with amotosalen (S-59) and UV light compared to FFP in healthy volunteers anticoagulated with warfarin
    Julie Hambleton
    Department of Medicine, General Clinical Research Center, Moffitt Hospital, University of California San Francisco, San Francisco, CA, USA
    Transfusion 42:1302-7. 2002
    ..To date, no clinical trials have characterized FFP infusion efficacy, and infusion still carries infectious risk. This single-blinded crossover study compared postinfusion kinetics of FVII in photochemically treated FFP to standard FFP...
  25. ncbi request reprint Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial
    Dick van Rhenen
    Sanquin Blood Bank South West Region, Rotterdam, The Netherlands
    Blood 101:2426-33. 2003
    ..Platelet components prepared with PCT offer the potential to further improve the safety of platelet transfusion using technology compatible with current methods to prepare buffy coat platelet components...
  26. ncbi request reprint How much do we know about the platelet transfusion threshold?
    Laurence Corash
    Transfusion 43:691-3. 2003
  27. ncbi request reprint Recovery and life span of 111indium-radiolabeled platelets treated with pathogen inactivation with amotosalen HCl (S-59) and ultraviolet A light
    Edward Snyder
    Yale University Medical School, Yale New Haven Hospital, New Haven, Connecticut, USA
    Transfusion 44:1732-40. 2004
    ..A photochemical treatment (PCT) method to inactivate pathogens in platelet concentrates has been developed. The system uses a psoralen, amotosalen HCl, coupled with ultraviolet A (UVA) illumination...
  28. ncbi request reprint Economics of pathogen inactivation technology for platelet concentrates in Japan
    Ulf Staginnus
    Premor Associates, New York, New York 10128, USA
    Int J Hematol 80:317-24. 2004
    ..Thus a preventive approach using pathogen inactivation with the IBS may be considered a desirable strategy for improving the current safety of platelet transfusions in Japan...
  29. ncbi request reprint Coagulation factor levels in cryosupernatant prepared from plasma treated with amotosalen hydrochloride (S-59) and ultraviolet A light
    Helen Yarranton
    Department of Haematology, University College London, London, United Kingdom
    Transfusion 45:1453-8. 2005
    ..This study compared the hemostatic variables of CSP prepared from FFP treated with a photochemical pathogen inactivation process to CSP prepared from conventional FFP...
  30. ncbi request reprint Polymerase chain reaction inhibition assay documenting the amotosalen-based photochemical pathogen inactivation process of platelet concentrates
    Iris Bruchmüller
    Institute of Transfusion Medicine and Immunology, Red Cross Blood Service of Baden Württemberg Hessen, Faculty of Clinical Medicine Mannheim, University of Heidelberg, Friedrich Ebert Strasse 107, 68167 Mannheim, Germany
    Transfusion 45:1464-72. 2005
    ....
  31. ncbi request reprint Therapeutic efficacy and safety of red blood cells treated with a chemical process (S-303) for pathogen inactivation: a Phase III clinical trial in cardiac surgery patients
    Richard J Benjamin
    Joint Program in Transfusion Medicine, Brigham and Women s Hospital, Boston, Massachusetts, USA
    Transfusion 45:1739-49. 2005
    ..A randomized, double-blind trial is reported of the clinical efficacy of red blood cells (RBCs) treated for pathogen inactivation with S-303, a synthetic labile alkylating agent...
  32. doi request reprint A prospective observational cohort safety study of 5106 platelet transfusions with components prepared with photochemical pathogen inactivation treatment
    Jean C Osselaer
    Blood Transfusion Center, Cliniques Universitaires de Mont Godinne, Universite Catholique de Louvain, Yvoir, Belgium
    Transfusion 48:1061-71. 2008
    ..A prospective cohort study was implemented to characterize the safety profile of this new PLT component in a broad patient population...